Cardiovascular disease: risk assessment and reduction, including lipid modification

Recommendation ID: CG181/2
Question: What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?
Any explanatory notes (if applicable): Why this is important: This guideline development process uses published summary data from trials in a meta-analysis to inform the clinical efficacy of statins. This use of aggregate data has limitations. The use of individual patient data would allow use of time to event statistics and allow investigation of interaction with baseline risk. Such an approach can be used to validate the current approach and would provide useful information on limitations of use of summary data.

Source guidance details

Comes from guidance: Cardiovascular disease: risk assessment and reduction, including lipid modification
Number: CG181
Date issued: July 2014

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	07/10/2014